BeOne Medicines Ltd. (ONC)
D
Pipeline Grade
Financial Position (from SEC Filings)
$4,853.4M
Cash & Equivalents
$201.3M
Quarterly Burn Rate
$237,318M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-31 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanc... | PHASE3 | Active Not Recruiting | 920 |
| NCT06093061 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | PHASE2 | Recruiting | 53 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.